Firstly, we found that the mRNA expression of RSK2 was significantly increased in A735-VR cells compared to the sensitive group in the GSE99923 dataset (Figure 4A). The mRNA level of RSK2 was further demonstrated higher in vemurafenib resistance A735-VR cells than that in A375 cells (Figure 4B)....These results not only reveal the presence of a RSK2-FOXO1-cyclin D1 signaling pathway in melanoma, but also provide a potential therapeutic strategy to enhance the efficacy of vemurafenib against cancer.